The global market for Q Fever was estimated at US$425.6 Million in 2024 and is projected to reach US$508.1 Million by 2030, growing at a CAGR of 3.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Q Fever market.
The growing incidence of zoonotic spillover events and intensified livestock production have prompted increased focus on Q Fever surveillance and diagnostics. Climate change, globalization of animal trade, and shifting land-use patterns are contributing to the spread of C. burnetii in previously unaffected geographies. Additionally, the bacterium's environmental resilience and potential for aerosol transmission underscore its biosecurity relevance. Public health authorities are now prioritizing integrated “One Health” strategies to control Q Fever outbreaks through coordinated veterinary and human health interventions.
Doxycycline is the standard treatment for acute Q Fever and remains the first-line therapy for high-risk occupational exposure. Chronic Q Fever, especially with cardiac involvement, requires prolonged treatment combining doxycycline with hydroxychloroquine. Vaccination plays a limited but significant role-Australia remains one of the few countries with an approved Q Fever vaccine (Q-Vax), primarily targeting agricultural workers. Efforts are underway to develop next-generation vaccines with broader safety profiles and mass immunization potential, especially in high-incidence regions like the Netherlands, parts of Africa, and Central Asia.
Public health responses are evolving to include early-warning systems, outbreak modeling, and mandatory disease notification protocols. The adoption of real-time GIS mapping, environmental sampling, and weather-based risk modeling is helping health authorities anticipate and pre-empt potential outbreaks. Integration of Q Fever monitoring into broader zoonotic disease surveillance frameworks is being supported by international bodies such as WHO, OIE, and FAO under the One Health Initiative. Regulatory alignment between veterinary and medical health systems is a key enabler for rapid containment and response coordination.
Heightened bio-preparedness and pandemic surveillance efforts post-COVID-19 are catalyzing government and institutional investments in zoonotic disease research, diagnostic capacity building, and rural health outreach programs. Regional Q Fever outbreaks in Australia, the Netherlands, Kenya, and China have led to increased funding for surveillance and research on vaccine development. Moreover, the integration of Q Fever into multi-pathogen biosurveillance systems is expanding the market for multiplex diagnostics and mobile laboratories.
Leading players in the space include bioMerieux, Thermo Fisher Scientific, QIAGEN, Ceva Sante Animale, and Alere (Abbott). Market growth is expected to accelerate as public health systems institutionalize Q Fever within national zoonotic disease frameworks, prioritize rural diagnostic access, and scale veterinary screening programs. As One Health approaches become central to infectious disease strategy, Q Fever is positioned to remain a critical zoonotic concern demanding sustained diagnostic and therapeutic innovation.
Segments: Type (Acute Q Fever, Chronic Q Fever); Medication Type (Antibiotics, Antimalarial, Corticosteroids, Other Medication Types); End-Use (Hospitals End-Use, Clinics End-Use, Research Institutes End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Global Q Fever Market - Key Trends & Drivers Summarized
Why Is Q Fever Emerging as a Public Health and Veterinary Surveillance Priority?
Q Fever, caused by the bacterium Coxiella burnetii, is a zoonotic disease that poses significant health risks to both humans and livestock. While often underdiagnosed, Q Fever outbreaks are increasingly documented across rural and peri-urban regions worldwide, where animal-human interface is pronounced. The disease primarily affects individuals in direct contact with farm animals, including veterinarians, abattoir workers, dairy farmers, and herders. In humans, Q Fever can present in acute or chronic forms, leading to febrile illness, pneumonia, or endocarditis in severe cases.The growing incidence of zoonotic spillover events and intensified livestock production have prompted increased focus on Q Fever surveillance and diagnostics. Climate change, globalization of animal trade, and shifting land-use patterns are contributing to the spread of C. burnetii in previously unaffected geographies. Additionally, the bacterium's environmental resilience and potential for aerosol transmission underscore its biosecurity relevance. Public health authorities are now prioritizing integrated “One Health” strategies to control Q Fever outbreaks through coordinated veterinary and human health interventions.
Which Diagnostics, Treatment Strategies, and At-Risk Populations Are Defining Market Dynamics?
Diagnosis of Q Fever relies on a combination of serological and molecular tests. Indirect immunofluorescence assay (IFA) remains the gold standard, while ELISA and PCR-based techniques are increasingly employed for both acute and chronic cases. Point-of-care diagnostics are being explored for field deployment in outbreak-prone rural settings. However, the low specificity of early clinical symptoms often leads to delayed diagnosis and inappropriate empirical treatment, increasing the risk of disease progression and complications.Doxycycline is the standard treatment for acute Q Fever and remains the first-line therapy for high-risk occupational exposure. Chronic Q Fever, especially with cardiac involvement, requires prolonged treatment combining doxycycline with hydroxychloroquine. Vaccination plays a limited but significant role-Australia remains one of the few countries with an approved Q Fever vaccine (Q-Vax), primarily targeting agricultural workers. Efforts are underway to develop next-generation vaccines with broader safety profiles and mass immunization potential, especially in high-incidence regions like the Netherlands, parts of Africa, and Central Asia.
How Are Biosecurity Measures, Disease Monitoring, and Regulatory Responses Influencing Control Strategies?
Enhanced veterinary surveillance and livestock management practices are central to Q Fever control. Measures such as animal quarantine, monitoring of parturition areas, proper disposal of placenta and manure, and control of animal movement are critical in reducing bacterial shedding and aerosol dispersion. In endemic zones, routine serological testing in goats, sheep, and cattle-along with culling or vaccination strategies-is being mandated to limit transmission risks.Public health responses are evolving to include early-warning systems, outbreak modeling, and mandatory disease notification protocols. The adoption of real-time GIS mapping, environmental sampling, and weather-based risk modeling is helping health authorities anticipate and pre-empt potential outbreaks. Integration of Q Fever monitoring into broader zoonotic disease surveillance frameworks is being supported by international bodies such as WHO, OIE, and FAO under the One Health Initiative. Regulatory alignment between veterinary and medical health systems is a key enabler for rapid containment and response coordination.
What Factors Are Driving the Growth of the Global Q Fever Diagnostics and Therapeutics Market?
The growth in the global Q Fever market is driven by rising disease awareness, improved diagnostic tools, and the increasing frequency of zoonotic disease outbreaks. Occupational exposure in livestock farming, animal transport, and veterinary practice continues to be a major driver of Q Fever incidence. The expansion of commercial livestock farming in developing economies, coupled with inadequate biosecurity practices, is amplifying human-animal pathogen transmission risks and driving demand for disease control solutions.Heightened bio-preparedness and pandemic surveillance efforts post-COVID-19 are catalyzing government and institutional investments in zoonotic disease research, diagnostic capacity building, and rural health outreach programs. Regional Q Fever outbreaks in Australia, the Netherlands, Kenya, and China have led to increased funding for surveillance and research on vaccine development. Moreover, the integration of Q Fever into multi-pathogen biosurveillance systems is expanding the market for multiplex diagnostics and mobile laboratories.
Leading players in the space include bioMerieux, Thermo Fisher Scientific, QIAGEN, Ceva Sante Animale, and Alere (Abbott). Market growth is expected to accelerate as public health systems institutionalize Q Fever within national zoonotic disease frameworks, prioritize rural diagnostic access, and scale veterinary screening programs. As One Health approaches become central to infectious disease strategy, Q Fever is positioned to remain a critical zoonotic concern demanding sustained diagnostic and therapeutic innovation.
Scope Of Study:
The report analyzes the Q Fever market in terms of units by the following Segments, and Geographic Regions/Countries:Segments: Type (Acute Q Fever, Chronic Q Fever); Medication Type (Antibiotics, Antimalarial, Corticosteroids, Other Medication Types); End-Use (Hospitals End-Use, Clinics End-Use, Research Institutes End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Acute Q Fever segment, which is expected to reach US$312.1 Million by 2030 with a CAGR of a 2.2%. The Chronic Q Fever segment is also set to grow at 4.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $115.9 Million in 2024, and China, forecasted to grow at an impressive 5.5% CAGR to reach $98.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Q Fever Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Q Fever Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Q Fever Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AtoxBio, Basilea Pharmaceutica Ltd, Bayer AG, BioMerieux SA, Ceva Santé Animale and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 34 companies featured in this Q Fever market report include:
- AtoxBio
- Basilea Pharmaceutica Ltd
- Bayer AG
- BioMerieux SA
- Ceva Santé Animale
- CSL Limited
- Elanco Animal Health
- Johnson & Johnson Services, Inc.
- Melinta Therapeutics, Inc.
- Merck KGaA
- Merck & Co., Inc.
- Pfizer Inc.
- QIAGEN N.V.
- Sanofi S.A.
- Teva Pharmaceutical Industries
- Thermo Fisher Scientific
- Valneva SE
- Vaxin Inc.
- Virbac
- Yashica Pharmaceuticals Pvt. Ltd
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AtoxBio
- Basilea Pharmaceutica Ltd
- Bayer AG
- BioMerieux SA
- Ceva Santé Animale
- CSL Limited
- Elanco Animal Health
- Johnson & Johnson Services, Inc.
- Melinta Therapeutics, Inc.
- Merck KGaA
- Merck & Co., Inc.
- Pfizer Inc.
- QIAGEN N.V.
- Sanofi S.A.
- Teva Pharmaceutical Industries
- Thermo Fisher Scientific
- Valneva SE
- Vaxin Inc.
- Virbac
- Yashica Pharmaceuticals Pvt. Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 367 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value in 2024 | 425.6 Million |
| Forecasted Market Value by 2030 | 508.1 Million |
| Compound Annual Growth Rate | 3.0% |
| Regions Covered | Global |
